New treatments like dotinurad provide safer, more effective solutions for millions battling gout and hyperuricemia.

If you suffered losses exceeding $100,000 in AstraZeneca between between February 23, 2022 and December 17, 2024 and would ...

Drugmakers have started 2025, implementing price hikes for 583 products within the first two days of the new year alone, ...

SAN DIEGO, CA / ACCESSWIRE / January 9, 2025 / Robbins LLP reminds investors that a class action was filed on behalf of all ...

The institute originally began reviewing Lynparza in this setting in 2018 but ended its review due to lack of evidence.

UBS has recently raised AstraZeneca PLC (AZN) stock to Neutral rating, as announced on November 20, 2024, according to Finviz. Earlier, on November 6, 2024, Deutsche Bank had raised the stock from a ...

Shares of AstraZeneca PLC AZN rose 2.18% to £109.88 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising 0.83% to 8,319.69.

When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...

As we enter 2025, many growth stocks are trading at high valuations and could be running out of room to rise in the near term ...

"It's fantastic news that olaparib has been approved for use on the NHS in England, providing a second targeted treatment option for certain people with locally advanced or secondary breast cancer who ...

The active substance of Kavigale is sipavibart, an antiviral human IgG1 monoclonal antibody discovered by RQ Bio in partnership with The University of Oxford. Sipavibart provides passive protection ...